Suppr超能文献

Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium.

作者信息

Mhyre Timothy R, Loy Rebekah, Tariot Pierre N, Profenno Louis A, Maguire-Zeiss Kathleen A, Zhang Dabao, Coleman Paul D, Federoff Howard J

机构信息

Center for Aging and Developmental Biology, Aab Institute for Biomedical Research, University of Rochester School of Medicine and Dentistry, Box 645, 601 Elmwood Avenue, Rochester, NY 14642, USA.

出版信息

Neurobiol Aging. 2008 Nov;29(11):1631-43. doi: 10.1016/j.neurobiolaging.2007.04.004. Epub 2007 May 22.

Abstract

The molecular profiling of peripheral tissues, including circulating leukocytes, may hold promise in the discovery of biomarkers for diagnosing and treating neurodegenerative diseases, including Alzheimer's disease (AD). As a proof-of-concept, we performed a proteomics study on peripheral leukocytes from patients with AD both before and during treatment with divalproex sodium. Using two-dimensional gel electrophoresis and MALDI-TOF mass spectrometry, we identified 10 differentially expressed proteins: two up-regulated proteins, 14-3-3 protein epsilon and peroxiredoxin 2; and eight down-regulated proteins, actin-interacting protein, mitogen activated protein kinase 1, beta actin, annexin A1, glyceraldehyde 3-phosphate dehydrogenase, transforming protein RhoA, acidic leucine-rich nuclear phosphoprotein 32 family member B, and a currently unidentified protein. A subset was validated on both the transcript and protein levels in normal human peripheral blood mononuclear cell cultures treated with valproic acid. These proteins comprise a number of functional classes that may be important to the biology of AD and to the therapeutic action of valproate. These data also suggest the potential of using peripheral leukocytes to monitor pharmaceutical action for neurodegenerative diseases.

摘要

相似文献

1
Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium.
Neurobiol Aging. 2008 Nov;29(11):1631-43. doi: 10.1016/j.neurobiolaging.2007.04.004. Epub 2007 May 22.
3
Proteomic profiling of brain cortex tissues in a Tau transgenic mouse model of Alzheimer's disease.
Biochem Biophys Res Commun. 2013 Jan 11;430(2):670-5. doi: 10.1016/j.bbrc.2012.11.093. Epub 2012 Dec 2.
4
Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer's disease.
Neurol Res. 2017 Mar;39(3):231-238. doi: 10.1080/01616412.2017.1281195. Epub 2017 Jan 20.
9
Identification of proteomic signatures associated with lung cancer and COPD.
J Proteomics. 2013 Aug 26;89:227-37. doi: 10.1016/j.jprot.2013.04.037. Epub 2013 May 9.
10
Dissecting Detergent-Insoluble Proteome in Alzheimer's Disease by TMTc-Corrected Quantitative Mass Spectrometry.
Mol Cell Proteomics. 2023 Aug;22(8):100608. doi: 10.1016/j.mcpro.2023.100608. Epub 2023 Jun 24.

引用本文的文献

1
Nanoparticle-Enabled Enrichment of Longitudinal Blood Proteomic Fingerprints in Alzheimer's Disease.
ACS Nano. 2021 Apr 27;15(4):7357-7369. doi: 10.1021/acsnano.1c00658. Epub 2021 Mar 17.
2
Identification of Blood Biomarkers for Alzheimer's Disease Through Computational Prediction and Experimental Validation.
Front Neurol. 2019 Jan 8;9:1158. doi: 10.3389/fneur.2018.01158. eCollection 2018.
3
Alzheimer's disease: are blood and brain markers related? A systematic review.
Ann Clin Transl Neurol. 2016 May 11;3(6):455-62. doi: 10.1002/acn3.313. eCollection 2016 Jun.
4
Mass spectrometry-based proteomics in Chest Medicine, Gerontology, and Nephrology: subgroups omics for personalized medicine.
Biomedicine (Taipei). 2014;4(4):25. doi: 10.7603/s40681-014-0025-y. Epub 2014 Nov 13.
6
Improved control of tuberculosis and activation of macrophages in mice lacking protein kinase R.
PLoS One. 2012;7(2):e30512. doi: 10.1371/journal.pone.0030512. Epub 2012 Feb 16.
7
Blood-based biomarkers of Alzheimer's disease: challenging but feasible.
Biomark Med. 2010 Feb;4(1):65-79. doi: 10.2217/bmm.09.84.
8
Chipping away at diagnostics for neurodegenerative diseases.
Neurobiol Dis. 2009 Aug;35(2):148-56. doi: 10.1016/j.nbd.2009.02.016. Epub 2009 Mar 10.

本文引用的文献

2
Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease.
Neurology. 2006 Feb 28;66(4):529-34. doi: 10.1212/01.wnl.0000198511.09968.b3.
3
Epigenetic therapy of cancer: past, present and future.
Nat Rev Drug Discov. 2006 Jan;5(1):37-50. doi: 10.1038/nrd1930.
6
Enhanced ROS-generation in lymphocytes from Alzheimer's patients.
Pharmacopsychiatry. 2005 Nov;38(6):312-5. doi: 10.1055/s-2005-916186.
8
A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers from their wild-type siblings.
Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14854-9. doi: 10.1073/pnas.0504178102. Epub 2005 Sep 30.
9
The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials.
Ann N Y Acad Sci. 2005 Aug;1053:195-204. doi: 10.1196/annals.1344.018.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验